Market Place
Sourcing Support
Hutchmed`s NDA For Tazemetostat In Follicular Lymphoma Accepted In China
03 Jul 2024 //
GLOBENEWSWIRE
CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance
29 Sep 2023 //
ONCLIVE
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat
11 Sep 2023 //
GLOBENEWSWIRE
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
13 Aug 2022 //
PRESS RELEASE
Epizyme Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Hutchmed begins dosing in follicular lymphoma therapy trial in China
01 Aug 2022 //
CLINICALTRIALSARENA
Ipsen snaps up Epizyme and cancer drug Tazverik for $247M
28 Jun 2022 //
FIERCEPHARMA
HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China
01 Jun 2022 //
GLOBENEWSWIRE
Epizyme to trim workforce and pipeline in cost-cutting plan
02 Mar 2022 //
FIERCEBIOTECH
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study
12 Dec 2021 //
BUSINESSWIRE
Epizyme Reports Q3 2021 Financial Results and Provides Business Update
09 Nov 2021 //
BUSINESSWIRE
Epizyme Announces Data from TAZVERIK Clinical Programs to be Presented ESMO 2021
14 Sep 2021 //
BUSINESSWIRE
"Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan
16 Aug 2021 //
PHARMABIZ
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK®
07 Oct 2020 //
BUSINESSWIRE
FDA Approvals Roundup: Tazverik, Crysvita, Xpovio
24 Jun 2020 //
RAPS
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO
13 May 2020 //
BIOSPACE
AZ sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review
14 Feb 2020 //
ENDPTS
Epizyme Announces FDA Acceptance of NDA for Filing Priority Review for TAZVERIK
14 Feb 2020 //
BUSINESSWIRE
Risdiplam FIREFISH Study Demonstrated Significant Improvement in Infants
23 Jan 2020 //
PR NEWSWIRE
FDA raises doubts about benefits of Epizyme`s cancer drug ahead of AdComm
18 Dec 2019 //
ENDPT NEWS
FDA’s in-house review offers bleak assessment of Epizyme’s tazemetostat
17 Dec 2019 //
ENDPTS
Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat
02 Dec 2019 //
BUSINESSWIRE
Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat
02 Dec 2019 //
BUSINESS WIRE
With FDA review nearing, Epizyme shares updated sarcoma data
03 Jun 2019 //
FIERCE BIOTECH
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat
30 May 2019 //
BUSINESSWIRE
Epizyme moves forward with cancer drug, eyes 2020 launch
30 May 2019 //
BIOPHARMADIVE
Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study
10 Oct 2018 //
BUSINESSWIRE
Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More
28 Sep 2018 //
XCONOMY
FDA lifts hold on Epizyme cancer drug, shares surge
24 Sep 2018 //
FDA gives Epizyme`s tazemetostat a green light on trial
24 Sep 2018 //
FDA Lifts Partial Clinical Hold on Epizyme`s Tazemetostat
24 Sep 2018 //
Epizyme Halts Phase II Trial of Tazemetostat in DLBCL
02 Aug 2018 //
GEN
Epizyme discards a failed program for tazemetostat — shares crater
02 Aug 2018 //
ENDPTS
Epizyme poaches SQZ Biotech, Tesaro vet Agarwal as CMO
23 Jul 2018 //
FIERCE BIOTECH
FDA slaps partial hold on Epizyme’s lead drug; analysts say ‘don’t panic’
24 Apr 2018 //
FIERCE BIOTECH
